Kidney disease in children and adolescents with perinatal HIV-1 infection

Journal of the International AIDS Society

Volumn 16, Issue , 2013, Pages

  Bhimma, Rajendra ^a   Purswani, Murli Udharam ^b   Kala, Udai ^c  

^a UNIVERSITY OF KWAZULU NATAL   (South Africa)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

Adolescents; Anti retroviral drug toxicity; Children; Human immunodeficiency virus; Kidney

Indexed keywords

ELECTROLYTE; TENOFOVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ACUTE KIDNEY FAILURE; CHRONIC KIDNEY DISEASE; ELECTROLYTE DISTURBANCE; END STAGE RENAL DISEASE; GLOMERULOPATHY; GLOMERULUS; HEMATURIA; HIV ASSOCIATED NEPHROPATHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INTERSTITIAL NEPHRITIS; KIDNEY DISEASE; NEPHROTOXICITY; PERINATAL INFECTION; PRIORITY JOURNAL; PROTEINURIA; RENAL REPLACEMENT THERAPY; REVIEW; URINARY TRACT INFECTION; ADOLESCENT; ADOLESCENTS; ANTI-RETROVIRAL DRUG TOXICITY; CHILD; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ISOLATION AND PURIFICATION; KIDNEY; PATHOLOGY; VIROLOGY;

ADOLESCENTS; ANTI-RETROVIRAL DRUG TOXICITY; CHILDREN; HUMAN IMMUNODEFICIENCY VIRUS; KIDNEY;

ADOLESCENT; ANTI-HIV AGENTS; CHILD; HIV INFECTIONS; HIV-1; HUMANS; KIDNEY DISEASES;

EID: 84887273098     PISSN: None     EISSN: 17582652     Source Type: Journal    
DOI: 10.7448/IAS.16.1.18596     Document Type: Review

References (167)

1. WHO. Treatment of children living with HIV. Global Health Sector Strategy in HIV/AIDS, 2011-2015 2013 September 2012 [cited 2013 Feb 19]. Available from: http://www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/ 2012/gr2012/JC2434-WorldAIDSday-results-en.pdf.
2. UNAIDS. Global report: UNAIDS report on the global AIDS epidemic 2010. 2010 [cited 2013 Feb 5]. Available from: http://www.unaids.org/globalreport/ Global-report.htm.
3. Rao TK, Filippone EJ, Nicastri AD, Landesman SH, Frank E, Chen CK, et al. Associated focal and segmental glomerulosclerosis in the acquired immunodeficiency syndrome. N Engl J Med. 1984;310(11):669-73.
4. Ross MJ, Klotman PE. Recent progress in HIV-associated nephropathy. J Am Soc Nephrol. 2002;13(12):2997-3004.
5. Szczech LA, Gupta SK, Habash R, Guasch A, Kalayjian R, Appel R, et al. The clinical epidemiology and course of the spectrum of renal diseases associated with HIV infection. Kidney Int. 2004;66(3):1145-52.
6. Selik RM Jr, Byers RH, Dworkin MS. Trends in diseases reported on U.S. death certificates that mentioned HIV infection, 1987-1999. J Acquir Immune Defic Syndr. 2002;29(4):378-87.
7. Trullas JC, Barril G, Cofan F, Moreno A, Cases A, Fernandez-Lucas M, et al. Prevalence and clinical characteristics of HIV type 1-infected patients receiving dialysis in Spain: results of a Spanish survey in 2006: GESIDA 48/05 study. AIDS Res Hum Retroviruses. 2008;24(10):1229-35.
8. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338(13):853-60.
9. Kaplan JE, Hanson D, Dworkin MS, Frederick T, Bertolli J, Lindegren ML, et al. Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy. Clin Infect Dis. 2000;30(Suppl 1):S5-14.
10. Naicker S, Fabian J. Risk factors for the development of chronic kidney disease with HIV/AIDS. Clin Nephrol. 2010;74(Suppl 1):S51-6.
11. Shahinian V, Rajaraman S, Borucki M, Grady J, Hollander WM, Ahuja TS. Prevalence of HIV-associated nephropathy in autopsies of HIV-infected patients. Am J Kidney Dis. 2000;35(5):884-8.
12. Daugas E, Rougier JP, Hill G. HAART-related nephropathies in HIV-infected patients. Kidney Int. 2005;67(2):393-403.
13. Ramsuran D, Bhimma R, Ramdial PK, Naicker E, Adhikari M, Deonarain J, et al. The spectrum of HIV-related nephropathy in children. Pediatr Nephrol. 2012;27(5):821-7.
14. Pardo V, Meneses R, Ossa L, Jaffe DJ, Strauss J, Roth D, et al. AIDS-related glomerulopathy: occurrence in specific risk groups. Kidney Int. 1987; 31(5):1167-73.
15. Strauss J, Abitbol C, Zilleruelo G, Scott G, Paredes A, Malaga S, et al. Renal disease in children with the acquired immunodeficiency syndrome. N Engl J Med. 1989;321(10):625-30.
16. Fauci AS. The AIDS epidemic-considerations for the 21st century. N Engl J Med. 1999;341(14):1046-50.
17. Mitsuya H, Weinhold KJ, Furman PA, St Clair MH, Lehrman SN, Gallo RC, et al. 3′-Azido-3′-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. Proc Natl Acad Sci USA. 1985;82(20):7096-100.
18. Purswani MU, Chernoff MC, Mitchell CD, Seage GR, 3rd, Zilleruelo G, Abitbol C, et al. Chronic kidney disease associated with perinatal HIV infection in children and adolescents. Pediatr Nephrol. 2012;27(6):981-9.
19. Estrella M, Fine DM, Gallant JE, Rahman MH, Nagajothi N, Racusen LC, et al. HIV type 1 RNA level as a clinical indicator of renal pathology in HIV-infected patients. Clin Infect Dis. 2006;43(3):377-80.
20. Winston JA. HIV and CKD epidemiology. Adv Chronic Kidney Dis. 2010; 17(1):19-25.
21. Kalayjian RC, Lau B, Mechekano RN, Crane HM, Rodriguez B, Salata RA, et al. Risk factors for chronic kidney disease in a large cohort of HIV-1 infected individuals initiating antiretroviral therapy in routine care. AIDS. 2012; 26(15):1907-15.
22. Wyatt CM, Meliambro K, Klotman PE. Recent progress in HIV-associated nephropathy. Annu Rev Med. 2012;63:147-59.
23. Ray PE. Taking a hard look at the pathogenesis of childhood HIV-associated nephropathy. Pediatr Nephrol. 2009;24(11):2109-19.
24. Conaldi PG, Bottelli A,Wade-Evans A, Biancone L, Baj A, Cantaluppi V, et al. HIV-persistent infection and cytokine induction in mesangial cells: a potential mechanism for HIV-associated glomerulosclerosis. AIDS. 2000;14(13): 2045-7.
25. Green DF, Resnick L, Bourgoignie JJ. HIV infects glomerular endothelial and mesangial but not epithelial cells in vitro. Kidney Int. 1992;41(4):956-60.
26. Tokizawa S, Shimizu N, Hui-Yu L, Deyu F, Haraguchi Y, Oite T, et al. Infection of mesangial cells with HIV and SIV: identification of GPR1 as a coreceptor. Kidney Int. 2000;58(2):607-17.
27. Barbiano di Belgiojoso G, Genderini A, Vago L, Parravicini C, Bertoli S, Landriani N. Absence of HIV antigens in renal tissue from patients with HIV-associated nephropathy. Nephrol Dial Transplant. 1990;5(7):489-92.
28. Eitner F, Cui Y, Hudkins KL, Stokes MB, Segerer S, Mack M, et al. Chemokine receptor CCR5 and CXCR4 expression in HIV-associated kidney disease. J Am Soc Nephrol. 2000;11(5):856-67.
29. Husain M, Gusella GL, Klotman ME, Gelman IH, Ross MD, Schwartz EJ, et al. HIV-1 Nef induces proliferation and anchorage-independent growth in podocytes. J Am Soc Nephrol. 2002;3(7):1806-15.
30. Husain M, D'Agati VD, He JC, Klotman ME, Klotman PE. HIV-1 Nef induces dedifferentiation of podocytes in vivo: a characteristic feature of HIVAN. AIDS. 2005;19(17):1975-80.
31. Zuo Y, Matsusaka T, Zhong J, Ma J, Ma LJ, Hanna Z, et al. HIV-1 genes vpr and nef synergistically damage podocytes, leading to glomerulosclerosis. J Am Soc Nephrol. 2006;17(10):2832-43.
32. Zhong J, Zuo Y, Ma J, Fogo AB, Jolicoeur P, Ichikawa I, et al. Expression of HIV-1 genes in podocytes alone can lead to the full spectrum of HIV-1-associated nephropathy. Kidney Int. 2005;68(3):1048-60.
33. Rosenstiel PE, Chan J, Snyder A, Planelles V, D'Agati VD, Klotman PE, et al. HIV-1 Vpr activates the DNA damage response in renal tubule epithelial cells. AIDS. 2009;23(15):2054-6.
34. Snyder A, Alsauskas ZC, Leventhal JS, Rosenstiel PE, Gong P, Chan JJ, et al. HIV-1 viral protein r induces ERK and caspase-8-dependent apoptosis in renal tubular epithelial cells. AIDS. 2010;24(8):1107-19.
35. Rosenstiel PE, Gruosso T, Letourneau AM, Chan JJ, LeBlanc A, Husain M, et al. HIV-1 Vpr inhibits cytokinesis in human proximal tubule cells. Kidney Int. 2008;74(8):1049-58.
36. Doublier S, Zennaro C, Spatola T, Lupia E, Bottelli A, Deregibus MC, et al. HIV-1 Tat reduces nephrin in human podocytes: a potential mechanism for enhanced glomerular permeability in HIV-associated nephropathy. AIDS. 2007;21(4):423-32.
37. Ray PE, Xu L, Rakusan T, Liu XH. A 20-year history of childhood HIV-associated nephropathy. Pediatr Nephrol. 2004;19(10):1075-92.
38. Connor E, Gupta S, Joshi V, DiCarlo F, Offenberger J, Minnefor A, et al. Acquired immunodeficiency syndrome-associated renal disease in children. J Pediatr. 1988;113(1 Pt 1):39-44.
39. Albaqumi M, Barisoni L. Current views on collapsing glomerulopathy. J Am Soc Nephrol. 2008;19(7):1276-81.
40. Kopp JB, Nelson GW, Sampath K, Johnson RC, Genovese G, An P, et al. APOL1 genetic variants in focal segmental glomerulosclerosis and HIVassociated nephropathy. J Am Soc Nephrol. 2011;22(11):2129-37.
41. Bostrom MA, Freedman BI. The spectrum of MYH9-associated nephropathy. Clin J Am Soc Nephrol. 2010;5(6):1107-13.
42. Nelson GW, Freedman BI, Bowden DW, Langefeld CD, An P, Hicks PJ, et al. Dense mapping of MYH9 localizes the strongest kidney disease associations to the region of introns 13 to 15. Hum Mol Genet. 2010;19(9):1805-15.
43. Genovese G, Friedman DJ, Ross MD, Lecordier L, Uzureau P, Freedman BI, et al. Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science. 2010;329(5993):841-5.
44. Tzur S, Rosset S, Shemer R, Yudkovsky G, Selig S, Tarekegn A, et al. Missense mutations in the APOL1 gene are highly associated with end stage kidney disease risk previously attributed to the MYH9 gene. Hum Genet. 2010; 128(3):345-50.
45. Purswani M, Patel K, Kopp J, Winkler C, Specter S, Hazra H, et al. Frequency of APOL1 risk alleles among a US cohort of children with perinatal HIV-1 infection and associations with renal phenotypes. In ESPR meeting. Philadelphia: Pediatric HIV/AIDS Cohort Study; 2013.
46. Kimmel PL, Phillips TM, Ferreira-Centeno A, Farkas-Szallasi T, Abraham AA, Garrett CT. HIV-associated immune-mediated renal disease. Kidney Int. 1993;44(6):1327-40.
47. Haas M, Kaul S, Eustace JA. HIV-associated immune complex glomerulonephritis with "lupus-like" features: a clinicopathologic study of 14 cases. Kidney Int. 2005;67(4):1381-90.
48. Bruggeman LA, Nelson PJ. Controversies in the pathogenesis of HIV-associated renal diseases. Nat Rev Nephrol. 2009;5(10):574-81.
49. McCulloch MI, Ray PE. Kidney disease in HIV-positive children. Semin Nephrol. 2008;28(6):585-94.
50. Balow JE. Nephropathy in the context of HIV infection. Kidney Int. 2005;67(4):1632-3.
51. Anochie IC, Eke FU, Okpere AN. Human immunodeficiency virus-associated nephropathy (HIVAN) in Nigerian children. Pediatr Nephrol. 2008;23(1): 117-22.
52. Gerntholtz TE, Goetsch SJ, Katz I. HIV-related nephropathy: a South African perspective. Kidney Int. 2006;69(10):1885-91.
53. Kala U, Petersen K, Faller G, Goetsch S. Spectrum of severe renal disease in children with HIV/Aids at Chris Hani Baragwanath Hospital, Johannesburg. Pediatr Nephrol. 2007;22:301.
54. Wearne N, Swanepoel CR, Boulle A, Duffield MS, Rayner BL. The spectrum of renal histologies seen in HIV with outcomes, prognostic indicators and clinical correlations. Nephrol Dial Transplant. 2012;27(11):4109-18.
55. Okpechi I, Swanepoel C, Duffield M, Mahala B,Wearne N, Alagbe S, et al. Patterns of renal disease in Cape Town South Africa: a 10-year review of a single-centre renal biopsy database. Nephrol Dial Transplant. 2011;26 (6):1853-61.
56. Ray PE, Rakusan T, Loechelt BJ, Selby DM, Liu XH, Chandra RS. Human immunodeficiency virus (HIV)-associated nephropathy in children from the Washington, D.C. area: 12 years' experience. Semin Nephrol. 1998;18(4): 396-405.
57. Steel-Duncan J, Miller M, Pierre RB, Dunkley-Thompson J, Palmer P, Evans-Gilbert T, et al. Renal manifestations in HIV-infected Jamaican children. West Indian Med J. 2008;57(3):246-52.
58. Nourse P, Bates W, Gajjar P, Sinclair P, Sinclair-Smith, McCulloch M. Paediatric HIV renal disease in Cape Town, South Africa. Pediatr Nephrol. 2007;22:1597.
59. Atta MG. Diagnosis and natural history of HIV-associated nephropathy. Adv Chronic Kidney Dis. 2010;17(1):52-8.
60. Lucas GM, Eustace JA, Sozio S, Mentari EK, Appiah KA, Moore RD. Highly active antiretroviral therapy and the incidence of HIV-1-associated nephropathy: a 12-year cohort study. AIDS. 2004;18(3):541-6.
61. Tarshish P. Guidelines for the care of children and adolescents with HIV infection. Approach to the diagnosis and management of HIV-associated nephropathy. J Pediatr. 1991;119(1 Pt 2):S50-2.
62. Ingulli E, Tejani A, Fikrig S, Nicastri A, Chen CK, Pomrantz A. Nephrotic syndrome associated with acquired immunodeficiency syndrome in children. J Pediatr. 1991;119(5):710-6.
63. Turner ME, Kher K, Rakusan T, D'Angelo L, Kapur S, Selby D, et al. A typical hemolytic uremic syndrome in human immunodeficiency virus-1-infected children. Pediatr Nephrol. 1997;11(2):161-3.
64. Chaparro AI, Mitchell CD, Abitbol CL, Wilkinson JD, Baldarrago G, Lopez E, et al. Proteinuria in children infected with the human immunodeficiency virus. J Pediatr. 2008;152(6):844-9.
65. Eke FU, Anochie IC, Okpere AN, Eneh AU, Ugwu RO, Ejilemele AA, et al. Microalbuminuria in children with human immunodeficiency virus (HIV) infection in Port Harcourt, Nigeria. Niger J Med. 2010;19(3):298-301.
66. Han TM, Naicker S, Ramdial PK, Assounga AG. A cross-sectional study of HIV-seropositive patients with varying degrees of proteinuria in South Africa. Kidney Int. 2006;69(12):2243-50.
67. Nourse PJ, Cotton MF, Bates WD. Renal manifestations in children co-infected with HIV and disseminated tuberculosis. Pediatr Nephrol. 2010;25(9): 1759-63.
68. Esezobor CI, Iroha E, Onifade E, Akinsulie AO, Temiye EO, Ezeaka C. Prevalence of proteinuria among HIV-infected children attending a tertiary hospital in Lagos, Nigeria. J Trop Pediatr. 2010;56(3):187-90.
69. Mistry BJ, Kala UK. Relevance of microalbuminuria in screening for HIV-associated nephropathy. Pediatr Nephrol. 2010;25:1870.
70. Joshi VV. Pathology of childhood AIDS. Pediatr Clin North Am. 1991;38(1): 97-120.
71. Tabatabai S, Sperati CJ, Atta MG, Janjua K, Roxbury C, Lucas GM, et al. Predictors of complication after percutaneous ultrasound-guided kidney biopsy in HIV-infected individuals: possible role of hepatitis C and HIV co-infection. Clin J Am Soc Nephrol. 2009;4(11):1766-73.
72. Parkhie SM, Fine DM, Lucas GM, Atta MG. Characteristics of patients with HIV and biopsy-proven acute interstitial nephritis. Clin J Am Soc Nephrol. 2010;5(5):798-804.
73. Berns JS, Cohen RM, Stumacher RJ, Rudnick MR. Renal aspects of therapy for human immunodeficiency virus and associated opportunistic infections. J Am Soc Nephrol. 1991;1(9):1061-80.
74. Bourgoignie JJ. Renal complications of human immunodeficiency virus type 1. Kidney Int. 1990;37(6):1571-84.
75. Olyaei AJ, deMattos AM, Bennett WM. Renal toxicity of protease inhibitors. Curr Opin Nephrol Hypertens. 2000;9(5):473-6.
76. Chugh S, Bird R, Alexander EA. Ritonavir and renal failure. N Engl J Med. 1997;336(2):138.
77. Kopp JB, Miller KD, Mican JA, Feuerstein IM, Vaughan E, Baker C, et al. Crystalluria and urinary tract abnormalities associated with indinavir. Ann Intern Med. 1997;127(2):119-25.
78. Carbone LG, Bendixen B, Appel GB. Sulfadiazine-associated obstructive nephropathy occurring in a patient with the acquired immunodeficiency syndrome. Am J Kidney Dis. 1988;12(1):72-5.
79. Dong BJ, Rodriguez RA, Goldschmidt RH. Sulfadiazine-induced crystalluria and renal failure in a patient with AIDS. J Am Board Fam Pract. 1999;12(3): 243-8.
80. Simon DI, Brosius FC 3rd, Rothstein DM. Sulfadiazine crystalluria revisited. The treatment of Toxoplasma encephalitis in patients with acquired immuno-deficiency syndrome. Arch Intern Med. 1990;150(11):2379-84.
81. Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P. Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care. 2004;8(4):R204-12.
82. Mehta RL, Kellum JA, Shah SV, Molitoris BA, Ronco C, Warnock DG, et al. Acute kidney injury network: report of an initiative to improve outcomes in acute kidney injury. Crit Care. 2007;11(2):R31.
83. Praga M, Gonzalez E. Acute interstitial nephritis. Kidney Int. 2010;77(11): 956-61.
84. Agarwal A, Soni A, Ciechanowsky M, Chander P, Treser G. Hyponatremia in patients with the acquired immunodeficiency syndrome. Nephron. 1989;53(4): 317-21.
85. Glassock RJ, Cohen AH, Danovitch G, Parsa KP. Human immunodeficiency virus (HIV) infection and the kidney. Ann Intern Med. 1990;112(1):35-49.
86. Tang WW, Kaptein EM, Feinstein EI, Massry SG. Hyponatremia in hospitalized patients with the acquired immunodeficiency syndrome (AIDS) and the AIDS-related complex. Am J Med. 1993;94(2):169-74.
87. Marks JB. Endocrine manifestations of human immunodeficiency virus (HIV) infection. Am J Med Sci. 1991;302(2):110-7.
88. Kalin MF, Poretsky L, Seres DS, Zumoff B. Hyporeninemic hypoaldosteronism associated with acquired immune deficiency syndrome. Am J Med. 1987; 82(5):1035-8.
89. De Beaudrap P, Diallo MB, Landman R, Gueye NF, Ndiaye I, Diouf A, et al. Changes in the renal function after tenofovir-containing antiretroviral therapy initiation in a Senegalese cohort (ANRS 1215). AIDS Res Hum Retroviruses. 2010;26(11):1221-7.
90. Deti EK, Thiebaut R, Bonnet F, Lawson-Ayayi S, Dupon M, Neau D, et al. Prevalence and factors associated with renal impairment in HIV-infected patients, ANRS C03 Aquitaine Cohort, France. HIV Med. 2010;11(5):308-17.
91. Wever K, van Agtmael MA, Carr A. Incomplete reversibility of tenofovirrelated renal toxicity in HIV-infected men. J Acquir Immune Defic Syndr. 2010; 55(1):78-81.
92. Cooper RD, Wiebe N, Smith N, Keiser P, Naicker S, Tonelli M. Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients. Clin Infect Dis. 2010;51(5):496-505.
93. Choi AI, Rodriguez RA, Bacchetti P, Volberding PA, Havlir D, Bertenthal D, et al. Low rates of antiretroviral therapy among HIV-infected patients with chronic kidney disease. Clin Infect Dis. 2007;45(12):1633-9.
94. Gupta SK, Eustace JA, Winston JA, Boydstun II, Ahuja TS, Rodriguez RA, et al. Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis. 2005;40(11):1559-85.
95. Asharam K, Bhimma R, Adhikari M. Human immunodeficiency virus and urinary tract infections in children. Ann Trop Paediatr. 2003;23(4):273-7.
96. Lanjewar DN, Ansari MA, Shetty CR, Maheshwari MB, Jain P. Renal lesions associated with AIDS-an autopsy study. Indian J Pathol Microbiol. 1999; 42(1):63-8.
97. Nadasdy T, Miller KW, Johnson LD, Hanson-Painton O, DeBault LE, Burns DK, et al. Is cytomegalovirus associated with renal disease in AIDS patients? Mod Pathol. 1992;5(3):277-82.
98. Frassetto LA, Tan-Tam C, Stock PG. Renal transplantation in patients with HIV. Nat Rev Nephrol. 2009;5(10):582-9.
99. Rashid A, Abboud O, Al-Kaabi S, Taha M, Ashour A, El-Sayed M. The impact of hepatitis C infection and antiviral therapy on clinical outcome in renal transplantation recipients. Saudi J Kidney Dis Transpl. 1999;10(1):31-5.
100. WHO. Antiretroviral therapy of HIV infection in infants and children: towards univesal access. 2006 [cited 2013 Apr 10]; 1-152]. Available from: http://www.who.int/hiv/pub/guidelines/art/en/print.html
101. Wyatt CM, Klotman PE. HIV-associated nephropathy in the era of antiretroviral therapy. Am J Med. 2007;120(6):488-92.
102. Smith MC, Austen JL, Carey JT, Emancipator SN, Herbener T, Gripshover B, et al. Prednisone improves renal function and proteinuria in human immunodeficiency virus-associated nephropathy. Am J Med. 1996;101(1): 41-8.
103. Weiner NJ, Goodman JW, Kimmel PL. The HIV-associated renal diseases: current insight into pathogenesis and treatment. Kidney Int. 2003;63(5): 1618-31.
104. Rao TK. Human immunodeficiency virus infection in end-stage renal disease patients. Semin Dial. 2003;16(3):233-44.
105. Novak JE, Szczech LA. Management of HIV-infected patients with ESRD. Adv Chronic Kidney Dis. 2010;17(1):102-10.
106. Jao J, Wyatt CM. Antiretroviral medications: adverse effects on the kidney. Adv Chronic Kidney Dis. 2010;17(1):72-82.
107. Kimmel PL, Barisoni L, Kopp JB. Pathogenesis and treatment of HIV-associated renal diseases: lessons from clinical and animal studies, molecular pathologic correlations, and genetic investigations. Ann Intern Med. 2003; 139(3):214-26.
108. Fine DM, Perazella MA, Lucas GM, Atta MG. Renal disease in patients with HIV infection: epidemiology, pathogenesis and management. Drugs. 2008;68(7):963-80.
109. Hammer SM, Eron JJ, Jr, Reiss P, Schooley RT, Thompson MA,Walmsley S, et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA. 2008;300(5):555-70.
110. Cohen SD, Chawla LS, Kimmel PL. Acute kidney injury in patients with human immunodeficiency virus infection. Curr Opin Crit Care. 2008;14(6): 647-53.
111. Kalayjian RC, Franceschini N, Gupta SK, Szczech LA, Mupere E, Bosch RJ, et al. Suppression of HIV-1 replication by antiretroviral therapy improves renal function in persons with low CD4 cell counts and chronic kidney disease. AIDS. 2008;22(4):481-7.
112. Fine DM, Perazella MA, Lucas GM, Atta MG. Kidney biopsy in HIV: beyond HIV-associated nephropathy. Am J Kidney Dis. 2008;51(3):504-14.
113. Kimmel PL, Mishkin GJ, Umana WO. Captopril and renal survival in patients with human immunodeficiency virus nephropathy. Am J Kidney Dis. 1996;28(2):202-8.
114. Yahaya I, Uthman AO, Uthman MM. Interventions for HIV-associated nephropathy. Cochrane Database Syst Rev. 2009;(4):CD007183.
115. Kiser JJ, Rutstein RM, Samson P, Graham B, Aldrovandi G, Mofenson LM, et al. Atazanavir and atazanavir/ritonavir pharmacokinetics in HIV-infected infants, children, and adolescents. AIDS. 2011;25(12):1489-96.
116. Couzigou C, Daudon M, Meynard JL, Borsa-Lebas F, Higueret D, Escaut L, et al. Urolithiasis in HIV-positive patients treated with atazanavir. Clin Infect Dis. 2007;45(8):e105-8.
117. Brewster UC, Perazella MA. Acute interstitial nephritis associated with atazanavir, a new protease inhibitor. Am J Kidney Dis. 2004;44(5):e81-4.
118. Nelson M, Azwa A, Sokwala A, Harania RS, Stebbing J. Fanconi syndrome and lactic acidosis associated with stavudine and lamivudine therapy. AIDS. 2008;22(11):1374-6.
119. Ahmad M. Abacavir-induced reversible Fanconi syndrome with nephrogenic diabetes insipidus in a patient with acquired immunodeficiency syndrome. J Postgrad Med. 2006;52(4):296-7.
120. Krishnan M, Nair R, Haas M, Atta MG. Acute renal failure in an HIVpositive 50-year-old man. Am J Kidney Dis. 2000;36(5):1075-8.
121. Crowther MA, Callaghan W, Hodsman AB, Mackie ID. Dideoxyinosine- associated nephrotoxicity. AIDS. 1993;7(1):131-2.
122. Izzedine H, Launay-Vacher V, Deray G. Fanconi syndrome associated with didanosine therapy. AIDS. 2005;19(8):844-5.
123. Perazella MA. Tenofovir-induced kidney disease: an acquired renal tubular mitochondriopathy. Kidney Int. 2010;78(11):1060-3.
124. Herlitz LC, Mohan S, Stokes MB, Radhakrishnan J, D'Agati VD, Markowitz GS. Tenofovir nephrotoxicity: acute tubular necrosis with distinctive clinical, pathological, and mitochondrial abnormalities. Kidney Int. 2010;78(11): 1171-7.
125. Fernandez-Fernandez B, Montoya-Ferrer A, Sanz AB, Sanchez-Nino MD, Izquierdo MC, Poveda J, et al. Tenofovir nephrotoxicity: 2011 update. AIDS Res Treat. 2011;2011:354908.
126. Szczech LA. Tenofovir nephrotoxicity: focusing research questions and putting them into clinical context. J Infect Dis. 2008;197(1):7-9.
127. Vigano A, Zuccotti GV, Martelli L, Giacomet V, Cafarelli L, Borgonovo S, et al. Renal safety of tenofovir in HIV-infected children: a prospective, 96-week longitudinal study. Clin Drug Investig. 2007;27(8):573-81.
128. Andiman WA, Chernoff MC, Mitchell C, Purswani M, Oleske J, Williams PL, et al. Incidence of persistent renal dysfunction in human immunodeficiency virus-infected children: associations with the use of antiretrovirals, and other nephrotoxic medications and risk factors. Pediatr Infect Dis J. 2009;28(7): 619-25.
129. Judd A, Boyd KL, Stohr W, Dunn D, Butler K, Lyall H, et al. Effect of tenofovir disoproxil fumarate on risk of renal abnormality in HIV-1-infected children on antiretroviral therapy: a nested case-control study. AIDS. 2010; 24(4):525-34.
130. Soler-Palacin P, Melendo S, Noguera-Julian A, Fortuny C, Navarro ML, Mellado MJ, et al. Prospective study of renal function in HIV-infected pediatric patients receiving tenofovir-containing HAART regimens. AIDS. 2011;25(2): 171-6.
131. Vigano A, Bedogni G, Manfredini V, Giacomet V, Cerini C, di Nello F, et al. Long-term renal safety of tenofovir disoproxil fumarate in vertically HIV-infected children, adolescents and young adults: a 60-month follow-up study. Clin Drug Investig. 2011;31(6):407-15.
132. Della Negra M, de Carvalho AP, de Aquino MZ, da Silva MT, Pinto J, White K, et al. A randomized study of tenofovir disoproxil fumarate in treatment-experienced HIV-1 infected adolescents. Pediatr Infect Dis J. 2012;31(5): 469-73.
133. Pontrelli G, Cotugno N, Amodio D, Zangari P, Tchidjou HK, Baldassari S, et al. Renal function in HIV-infected children and adolescents treated with tenofovir disoproxil fumarate and protease inhibitors. BMC Infect Dis. 2012;12(1):18.
134. Purswani M, Patel K, Kopp JB, Seage GR, 3rd, Chernoff MC, Hazra R, et al. Tenofovir treatment duration predicts proteinuria in a multi-ethnic United States cohort of children and adolescents with perinatal HIV-1 infection. Pediatr Infect Dis J. 2012;32(5):495-500.
135. Mandayam S, Ahuja TS. Dialyzing a patient with human immunodeficiency virus infection: what a nephrologist needs to know. Am J Nephrol. 2004;24(5):511-21.
136. Panel de expertos del Grupo de Estudio de Sida y del Plan Nacional sobre el Sida (PNS). [Diagnosis, treatment and prevention of renal diseases in HIV infected patients. Recommendations of the Spanish AIDS Study Group/National AIDS Plan]. Enferm Infecc Microbiol Clin. 2010;28(8):520. e1-22.
137. Mokrzycki MH, Schroppel B, von Gersdorff G, Rush H, Zdunek MP, Feingold R, et al. Tunneled-cuffed catheter associated infections in hemodialysis patients who are seropositive for the human immunodeficiency virus. J Am Soc Nephrol. 2000;11(11):2122-7.
138. Brock JS, Sussman M,Wamsley M, Mintzer R, Baumann FG, Riles TS, et al. The influence of human immunodeficiency virus infection and intravenous drug abuse on complications of hemodialysis access surgery. J Vasc Surg. 1992;16(6):904-10; discussion 911-2.
139. Mitchell D, Krishnasami Z, Young CJ, Allon M. Arteriovenous access outcomes in haemodialysis patients with HIV infection. Nephrol Dial Transplant. 2007;22(2):465-70.
140. Ortiz C, Meneses R, Jaffe D, Fernandez JA, Perez G, Bourgoignie JJ. Outcome of patients with human immunodeficiency virus on maintenance hemodialysis. Kidney Int. 1988;34(2):248-53.
141. Tourret J, Tostivint I, du Montcel ST, Bragg-Gresham J, Karie S, Vigneau C, et al. Outcome and prognosis factors in HIV-infected hemodialysis patients. Clin J Am Soc Nephrol. 2006;1(6):1241-7.
142. Gordillo R, Kumar J, Del Rio M, Flynn JT, Woroniecki RP. Outcome of dialysis in children with human immunodeficiency virus infection. Pediatr Nephrol. 2009;24(1):171-5.
143. Gordillo R, Del Rio M, Woroniecki RP. Dialysis-associated morbidity, ultrafiltration, and cardiovascular variables in children with HIV infection. Clin Nephrol. 2011;75(5):434-9.
144. Stock PG, Roland ME. Evolving clinical strategies for transplantation in the HIV-positive recipient. Transplantation. 2007;84(5):563-71.
145. Andrieu JM, Even P, Venet A, Tourani JM, Stern M, Lowenstein W, et al. Effects of cyclosporin on T-cell subsets in human immunodeficiency virus disease. Clin Immunol Immunopathol. 1988;47(2):181-98.
146. Groux H, Torpier G, Monte D, Mouton Y, Capron A, Ameisen JC. Activation-induced death by apoptosis in CD4+ T cells from human immunodeficiency virus-infected asymptomatic individuals. J Exp Med. 1992; 175(2):331-40.
147. Schwarz A, Offermann G, Keller F, Bennhold I, L'Age-Stehr J, Krause PH, et al. The effect of cyclosporine on the progression of human immunodeficiency virus type 1 infection transmitted by transplantation-data on four cases and review of the literature. Transplantation. 1993;55(1):95-103.
148. Streblow DN, Kitabwalla M, Malkovsky M, Pauza CD. Cyclophilin a modulates processing of human immunodeficiency virus type 1 p55Gag: mechanism for antiviral effects of cyclosporin A. Virology. 1998;245(2): 197-202.
149. Rizzardi GP, Harari A, Capiluppi B, Tambussi G, Ellefsen K, Ciuffreda D, et al. Treatment of primary HIV-1 infection with cyclosporin A coupled with highly active antiretroviral therapy. J Clin Invest. 2002;109(5):681-8.
150. Samaniego M, Becker BN, Djamali A. Drug insight: maintenance immunosuppression in kidney transplant recipients. Nat Clin Pract Nephrol. 2006;2(12):688-99.
151. Ciuffreda D, Pantaleo G, Pascual M. Effects of immunosuppressive drugs on HIV infection: implications for solid-organ transplantation. Transpl Int. 2007;20(8):649-58.
152. Heredia A, Margolis D, Oldach D, Hazen R, Le N, Redfield R. Abacavir in combination with the inosine monophosphate dehydrogenase (IMPDH)-inhibitor mycophenolic acid is active against multidrug-resistant HIV-1. J Acquir Immune Defic Syndr. 1999;22(4):406-7.
153. Margolis D, Heredia A, Gaywee J, Oldach D, Drusano G, Redfield R. Abacavir and mycophenolic acid, an inhibitor of inosine monophosphate dehydrogenase, have profound and synergistic anti-HIV activity. J Acquir Immune Defic Syndr. 1999;21(5):362-70.
154. Heredia A, Latinovic O, Gallo RC, Melikyan G, Reitz M, Le N, et al. Reduction of CCR5 with low-dose rapamycin enhances the antiviral activity of vicriviroc against both sensitive and drug-resistant HIV-1. Proc Natl Acad Sci U S A. 2008;105(51):20476-81.
155. Roland ME, Barin B, Carlson L, Frassetto LA, Terrault NA, Hirose R, et al. HIV-infected liver and kidney transplant recipients: 1- and 3-year outcomes. Am J Transplant. 2008;8(2):355-65.
156. Kumar MS, Sierka DR, Damask AM, Fyfe B, McAlack RF, Heifets M, et al. Safety and success of kidney transplantation and concomitant immunosuppression in HIV-positive patients. Kidney Int. 2005;67(4):1622-9.
157. Gruber SA, Doshi MD, Cincotta E, Brown KL, Singh A, Morawski K, et al. Preliminary experience with renal transplantation in HIV+ recipients: low acute rejection and infection rates. Transplantation. 2008;86(2):269-74.
158. Peter Stock MR. Solid organ transplantation in HIV: multi-site study. San Franscisco: EMMES Corporation; 2009. p. 1-82.
159. Frassetto LA, Browne M, Cheng A, Wolfe AR, Roland ME, Stock PG, et al. Immunosuppressant pharmacokinetics and dosing modifications in HIV-1 infected liver and kidney transplant recipients. Am J Transplant. 2007;7(12): 2816-20.
160. Niwa T, Murayama N, Emoto C, Yamazaki H. Comparison of kinetic parameters for drug oxidation rates and substrate inhibition potential mediated by cytochrome P450 3A4 and 3A5. Curr Drug Metab. 2008;9(1): 20-33.
161. Jain AK, Venkataramanan R, Shapiro R, Scantlebury VP, Potdar S, Bonham CA, et al. The interaction between antiretroviral agents and tacrolimus in liver and kidney transplant patients. Liver Transpl. 2002;8(9):841-5.
162. Engels EA, Biggar RJ, Hall HI, Cross H, Crutchfield A, Finch JL, et al. Cancer risk in people infected with human immunodeficiency virus in the United States. Int J Cancer. 2008;123(1):187-94.
163. Vajdic CM, McDonald SP, McCredie MR, van Leeuwen MT, Stewart JH, Law M, et al. Cancer incidence before and after kidney transplantation. JAMA. 2006;296(23):2823-31.
164. MacDonald DC, Nelson M, Bower M, Powles T. Hepatocellular carcinoma, human immunodeficiency virus and viral hepatitis in the HAART era. World J Gastroenterol. 2008;14(11):1657-63.
165. Roland ME, Stock PG. Review of solid-organ transplantation in HIV-infected patients. Transplantation. 2003;75(4):425-9.
166. Anonymous. Kidney disease in HIV-infected patients. New York: State Department of Health AIDS Institute; 2013.
167. Lescure FX, Flateau C, Pacanowski J, Brocheriou I, Rondeau E, Girard PM, et al. HIV-associated kidney glomerular diseases: changes with time and HAART. Nephrol Dial Transplant. 2012;27(6):2349-55.